期刊文献+

鲍曼不动杆菌耐药性及β内酰胺酶基因型研究 被引量:86

Study on the resistance and genotyping of β-lactamases in Acinetobacter baumannii
原文传递
导出
摘要 目的 明确浙江湖州地区临床分离的鲍曼不动杆菌耐药性及 β内酰胺酶基因型。方法 采用ATB药敏试验条板微量肉汤法测定临床分离的 6 0株鲍曼不动杆菌对 18种抗菌药物的敏感性 ,采用聚合酶链反应 (PCR)及序列分析的方法分析 β内酰胺酶基因型。 结果 鲍曼不动杆菌对亚胺培南、美洛培南的耐药率为 1 7% ,哌拉西林 /他唑巴坦的耐药率为 4 8 3% ,对其他抗菌药物的耐药率均在 5 0 %以上。有 18株菌株扩增到SHV型 β内酰胺酶 ,17株为ESBLsSHV 12 ,另 1株(HZ0 1株 )扩增序列全长含 82 6个核苷酸 ,与SHV 1相比 ,第 35、191、2 38、2 4 0位氨基酸有不同 ,被命名为SHV 4 8(GenBank登录号 :AY2 5 916 4 )。结论 浙江湖州地区临床分离的鲍曼不动杆菌耐药严重 ,至少存在 3种不同类型的 β内酰胺酶 ,基因型分别为SHV 12、SHV 4 8、TEM 1。 Objective To investigate the resistance and genotyping of β-Lactamases in Acinetobacter baumannii isolated from Huzhou, Zhejiang province. Methods Microdilute tests were performed to detect the susceptibility of 18 kinds of antimicrobial agents against 60 strains of A cinetobacter baumannii Genotypes of β-lactamases was analyzed by PCR and verificated by DNA sequencing. Results The resistant rates of 60 strains to Imipenam, Meropenem and Piperacillin/ Tazobactam were 1.7%, 1.7% and 48.3%, respectively. The resistant rates to other antimicrobial agents were more than 50%. SHV type β-lactamases were positive in 18 of 60 isolates tested, 17 of which were SHV-12. The other strain (HZ01) was amplicated the sequence including 826 nucleotides, which has the amino acid mutations in position 35, 191, 238 and 240 compared with SHV-1. It is a new SHV type β-lactamases nominated SHV-48 (GenBank number: AY259164).Conclusion The resistance of Acinetobacter baumannii isolated from Huzhou of Zhejiang province was a serious issue and at least 3 kinds of β-lactamases exsisted including SHV-12, SHV-48 and TEM-1.
出处 《中华检验医学杂志》 CAS CSCD 北大核心 2003年第11期683-685,共3页 Chinese Journal of Laboratory Medicine
关键词 鲍曼不动杆菌 耐药性 Β内酰胺酶 基因型 抗菌药物 Acinetobacter Beta-lactamases Gene Sequence analysis
  • 相关文献

参考文献7

二级参考文献27

  • 1郭晓君.蛋白质电泳试验技术[M].北京:科学出版社,1999.161-210.
  • 2Jing Jouy,J Clin Microbiol,2000年,38卷,4320页
  • 3徐英春,中华医学检验杂志,1999年,22卷,355页
  • 4郭晓君,蛋白质电泳试验技术,1999年,161页
  • 5Ma L,Antimicrob Agents Chemother,1998年,42卷,1181页
  • 6Bergogne-Berezin E. Guideline on antimicrobial chemotherapy for prevention and treatment of infections in the ICU. J Chemother, 2001,1: 134-149.
  • 7Goossens H. MYSTIC program: summary of European data from 1997 to 2000. Diagn Microbiol Infect Dis, 2001, 41: 183-189.
  • 8Leblebicioglu H, Gunaydin M, Esen S, et al. Surveillance of antimicrobial resistance in gram-negative isolates from ICU in Turkey:analysis of data from the last 5 years. J Chemother, 2002, 14:140-146.
  • 9Karlowsky JA, Kelly LJ, Thornsberry C , et al. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000:TRUST and TSN data for the United States. J Autimicrob Agents , 2002,19: 21-31.
  • 10National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing. Approved standard M100-S12. National Committee for Clinical Laboratory Standards,Wayne, Pa.2002,1.

共引文献1028

同被引文献653

引证文献86

二级引证文献634

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部